Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0215 • ACR Convergence 2020
Incidence and Risk of Venous Thromboembolic Events Among Patients with Rheumatoid Arthritis Enrolled in the Upadacitinib Clinical Trial Program
Ernest Choy¹, Iain McInnes², John Cush³, Jacob Aelion⁴, William Rigby⁵, Yanna Song⁶, Sebastian Meerwein⁷, John Liu⁸, Nasser Khan⁸, Jessica Suboticki⁸ and Alexander Cohen⁹, ¹CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ²Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³University of Texas Southwestern Medical School, Dallas, TX, ⁴Arthritis Clinic PLLC, Jackson, ⁵Dartmouth College, Norwichi, VT, ⁶AbbVie Inc., North Chicago,, IL, ⁷Pharmaceutical Development, AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ⁸AbbVie Inc., North Chicago, IL, ⁹Guy’s and St Thomas’ NHS FT Hospitals, King’s College, London, United Kingdom
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) are at an increased risk for the development of venous thromboembolism (VTE, including pulmonary embolism [PE] and deep…
Abstract Number: 0232 • ACR Convergence 2020
Safety and Effectiveness of Tocilizumab in Patients with Renal Insufficiency in the Non-interventional Study ICHIBAN
Christof Specker¹, Martin Aringer², Gerd Burmester³, Johannes Gerlach⁴, Michael Hofmann⁵, Herbert Kellner⁶, Frank Moosig⁷, Hans-Peter Tony⁸ and Gerhard Fliedner⁹, ¹Clinic Essen-Mitte, Essen, Germany, ²Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, Dresden, Germany, ³Charité University Hospital Berlin, Berlin, Germany, ⁴Roche Pharma AG, Grenzach-Wyhlen, Germany, ⁵Chugai, Frankfurt am Main, Germany, ⁶Rheumatology and Gastroenterology Specialty Practice, Munich, Germany, ⁷Rheumatology Center Schleswig-Holstein Middle, Neumünster, Germany, ⁸Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany, ⁹Rheumatology Practice, Onsabrück, Germany
Background/Purpose: RA increases a patient’s systemic inflammatory burden, which has been associated with development of chronic kidney disease (CKD), especially in patients with comorbid hypertension,…
Abstract Number: 0452 • ACR Convergence 2020
Recombinant Zoster Vaccine in Patients with Rheumatic Diseases: A Retrospective Study of 622 Patients
Tiphaine Lenfant¹, Elizabeth Kirchner², Rula Hajj-ali³, Leonard Calabrese³ and Cassandra Calabrese³, ¹Cleveland Clinic Foundation, Rocky River, OH, ²Cleveland Clinic Foundation, Cleveland, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: The recombinant herpes zoster vaccine (RZV) was FDA-approved in 2017 but patients with rheumatic diseases were excluded from initial pivotal trials because of theoretical…
Abstract Number: 0493 • ACR Convergence 2020
Automatic Joint Space Assessment in Hand Radiographs with Deep Learning Among Patients with Rheumatoid Arthritis
Yun-Ju Huang¹, Chang-Fu Kuo¹, Fakai Wang², Shun Miao², Kang Zheng² and Le Lu², ¹Chang Gung Memorial Hospital, Taoyuan, Taiwan (Republic of China), ²PAII labs, Bethesda, MD
Background/Purpose: Assessment of joint space is the fundamental radiographic task to diagnose rheumatoid arthritis (RA) and to assess the severity and progression of the disease.…
Abstract Number: 0740 • ACR Convergence 2020
Card9 Promotes Th17-mediated Arthritis and Spondylitis via Control of Acute Pathogenic Neutrophil Responses in SKG Mice
Holly Rosenzweig¹, Emily Vance¹, Ellen Lee¹ and Ruth Napier¹, ¹Oregon Health & Science University and VA Portland Health Care System, Portland, OR
Background/Purpose: Caspase recruitment domain-containing protein 9 (CARD9) is an intracellular signal transduction molecule that mediates antimicrobial responses following activation of C-type lectin receptors (ie. Dectin-1) by…
Abstract Number: 0757 • ACR Convergence 2020
Sunlight Exposure, Sun-protective Behaviour, and Anti-citrullinated Protein Antibody Positivity: A General Population-based Study in Quebec, Canada
Naizhuo Zhao¹, Audrey Smargiassi², Ines Colmegna³, Marie Hudson⁴, Marvin Fritzler⁵ and Sasha Bernatsky⁶, ¹McGill University, Montreal, Canada, ²l’Université de Montréal, Montreal, Canada, ³The Research Institute of the McGill University Health Centre, Montreal, Canada, ⁴Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ⁵Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁶The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Sunlight exposure has been associated with lower rheumatoid arthritis (RA) risk, but to our knowledge, no one has ever studied sunlight exposure and anti-citrullinated…
Abstract Number: 0775 • ACR Convergence 2020
T and B Cell Responses to Common Tenascin-C Peptides in RA
JING Song¹, Anja Schwenzer², Sara Turcinov³, Alicia Wong², Cliff Rims¹, Lorena Rodriguez Martinez², David Arribas-Layton⁴, Christina Gerstner⁵, Virginia Muir⁶, Jeffrey Carlin⁷, Kim Midwood², Vivianne Malmström⁸, Eddie James¹ and Jane Buckner¹, ¹Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Institutet, Stockholm, Sweden, ⁴Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, ⁵Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁷Department of Rheumatology, Virginia Mason Medical Center, Seattle, WA, ⁸Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Although autoreactive CD4+ T cell and antibody responses against citrullinated antigens are known to contribute to loss of immune tolerance in rheumatoid arthritis (RA),…
Abstract Number: 0792 • ACR Convergence 2020
LY294002 Improves the Collagen-induced Arthritis by Inducing Neutrophil Apoptosis
Xuechan Huang¹, Tianwang Li¹, Shuyang Chen¹, Zhixiang Huang¹ and Junming Chen¹, ¹Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangdong, China (People's Republic)
Background/Purpose: Neutrophils play a central role in host defense, but they also play important effectors on acute and chronic inflammation. Neutrophil apoptosis is essential for…
Abstract Number: 0808 • ACR Convergence 2020
Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate: Real World Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Angela Cesta², Xiuying Li³, Edward C Keystone⁴ and Claire Bombardier⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, Canada, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Institute for Work and Health, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX). TOFA can…
Abstract Number: 0825 • ACR Convergence 2020
Sex Differences in the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis Patients: A Post Hoc Analysis of Phase 3 and Long-Term Extension Trials
Niall Jones¹, Vibeke Strand², Hendrik Schulze-Koops³, Eduardo Mysler⁴, Cassandra D Kinch⁵, David Gruben⁶, Rebecca Germino⁷, Carol A Connell⁶ and Lihi Eder⁸, ¹Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, ²Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ³Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ⁴Organización Médica de Investigación, Buenos Aires, Argentina, ⁵Pfizer Canada ULC, Kirkland, QC, Canada, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, New York, NY, ⁸Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Differences in efficacy outcomes favoring male vs female patients (pts) with RA have been reported with csDMARDs1 and TNF inhibitors;2 results with JAK inhibitors…
Abstract Number: 0968 • ACR Convergence 2020
Combined Inhibition of Autophagy and Glutamine Metabolism Suppresses Cell Growth of RA Synoviocytes and Ameliorates Arthritis in SKG Mice
Ikuko Naka¹, Jun Saegusa², Kenichi Uto², Yuzuru Yamamoto³, Yoshihide Ichise⁴, Hirotaka Yamada⁴, Yo Ueda⁵, Takaichi Okano⁴, Soshi Takahashi⁶, Sho Sendo⁷ and Akio Morinobu⁸, ¹Kobe University, Kobe, ²Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan, ³Kobe University, Kobe-city, Japan, ⁴Kobe University, Kobe, Japan, ⁵Kobe UniversityRheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan, ⁶Kobe univerity, Kobe, Japan, ⁷Kobe university, Kobe city, Japan, ⁸Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan
Background/Purpose: Immunometabolism is now recognaized to be crucial in the pathogenesis of rheumatoid arthritis (RA). We have recently shown that the expression of glutaminase 1…
Abstract Number: 1006 • ACR Convergence 2020
Post-menopausal Rheumatoid Arthritis Is Inversely Associated with Lifetime High Level of Estrogen Exposure in the French E3N Cohort
Carine Salliot¹, Yann Nguyen², Amandine Gelot³, Xavier Mariette⁴, Marie-Christine Boutron-Ruault³ and Raphaèle Seror⁵, ¹CHR orleans, Orleans, France, ²1Department of Internal Medicine, Hôpital Beaujon, APHP Nord, Université de Paris, Clichy, Clichy, France, ³Institut Gustave Roussy, Villejuif, France, ⁴Paris-Sud University, Rueil-Malmaison, France, ⁵Rheumatology Department, Bicetre Hospital, APHP, France, Paris, France
Background/Purpose: The involvement of female hormones in the pathogenesis of Rheumatoid Arthritis (RA) is supported by numerous observations: a female predominance, an increased incidence in…
Abstract Number: 1141 • ACR Convergence 2020
Reversing Seasonal Decline of T2T Outcome in RA Patients Under Double Hits by Chinese New Year and COVID-19 Epidemic via Online Interaction with SSDM
Rong Mu¹, Hongbin Li², Zhanyun Da³, Anbin Huang⁴, Hongzhi Wang⁵, Jing Lu⁶, Jianhong Wu⁷, Shengtao Zhang⁸, Yikai Yu⁹, Chun Li¹⁰, Shouxin Li⁹, Peng Ji¹¹, Hua Wei¹², Bin Wu¹³, Zhenbin Li¹⁴, Lingxun Shen¹⁵, Yanping Zhao¹⁶, Yi Zhao¹⁷, Xiaoqiang Hou¹⁸, Hui Xiao¹⁹, Yuhua Jia²⁰, Bing Wu²⁰, Yonggang Zhao²⁰, Xin Chen¹⁹, Miaomiao Song²⁰, Fei Xiao²⁰ and Zhanguo Li²¹, ¹People's Hospital, Beijing University Medical School, Beijing, Beijing, China (People's Republic), ²The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), ³The affiliated Hospital of Nantong University, Nantong, Jiangsu, China (People's Republic), ⁴Union Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology, WuHan, China (People's Republic), ⁵The First Hospital of Jiaxing, Jiaxing, China (People's Republic), ⁶First Affiliated Hospital of China Medical University, Shenyang, China (People's Republic), ⁷Department of Rheumatology, Dazhou Central Hospital, Dazhou, China (People's Republic), ⁸Tongji Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China (People's Republic), ⁹Tongji Hospital Affiliated to Tongji Medical College of HUST, Wuhan, Hubei, China (People's Republic), ¹⁰People's Hospital, Beijing University Medical School, beijing, China (People's Republic), ¹¹The first affiliated hospital of xinjiang medical university, Urumqi, Xinjiang, China (People's Republic), ¹²Northern Jiangsu People's Hospital, Yangzhou, China (People's Republic), ¹³Chongqing Hospital of Traditional Chinese Medicine, chongqing, China (People's Republic), ¹⁴Chinese people ’s liberation army joint service support force 980 hospital, shijiazhuang, Jiangxi, China (People's Republic), ¹⁵Union Hospital Affiliated Tongji Medical College of HUST, Wuhan, Hubei, China (People's Republic), ¹⁶First Affiliated Hospital of Harbin Medical University, Harbin, China (People's Republic), ¹⁷Xuanwu Hospital, Capital Medical University, Beijing, China, Beijing, China (People's Republic), ¹⁸Yichang Central People's Hospital, Beijing, China (People's Republic), ¹⁹Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ²⁰Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), ²¹Peking University People’s Hospital, Xicheng, Beijing, China (People's Republic)
Background/Purpose: Treat-to-target (T2T), achieving a DAS28 below 3.2 is the main management strategy for RA. The Chinese New Year is a long holiday started in…
Abstract Number: 1193 • ACR Convergence 2020
Unsupervised Molecular Profile Clustering in the Serum of Rheumatoid Arthritis Patients Identifies Groups with Differential CV-risk SCORE: Modulation by Biological Therapies
Maria Luque-Tevar¹, Carlos Pérez-Sánchez¹, Pilar Font², Alejandra Maria Patiño-Trives¹, Montserrat Romero-Gomez², Desirée Ruiz-Vilchez², Sara Remuzgo-Martínez³, Raquel López-Mejías⁴, Iván Arias de la Rosa¹, Carmen Torres-Granados¹, María-Carmen Abalos-Aguilera¹, Rafaela Ortega-Castro², Alejandro Escudero-Contreras², Carlos Rodriguez-Escalera⁵, Jose Perez-Venegas⁶, Mª Dolores Ruiz-Montesinos⁶, Carmen Dominguez⁶, Carmen Romero-Barco⁷, Antonio Fernandez-Nebro⁸, Natalia Mena-Vazquez⁹, Jose Luis Marenco¹⁰, Julia Uceda-Montañez¹⁰, Mª Dolores Toledo-Coello¹¹, Nuria Barbarroja¹, M Angeles Aguirre², Eduardo Collantes², Miguel A Gonzalez-Gay¹² and Chary Lopez-Pedrera¹, ¹Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ³Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Santander, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁵Hospital Universitario de Jaen, Jaén, Spain, ⁶Hospital Universitario Virgen Macarena, Sevilla, Sevilla, Spain, ⁷Hospital Clínico Universitario, Málaga, Málaga, Spain, ⁸University of Malaga, Malaga, Spain, ⁹Hospital Regional Universitario de Málaga, Málaga, Spain, ¹⁰Hospital Universitario Virgen de Valme, Sevilla, Sevilla, Spain, ¹¹Hospital Universitario de Jerez de la Frontera, Cádiz, Spain, Cádiz, Spain, ¹²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander
Background/Purpose: To identify specific molecular profiles associated to the enhanced cardiovascular (CV)-risk present in Rheumatoid Arthritis (RA) patients and their modulation by biologic disease modifying…
Abstract Number: 1209 • ACR Convergence 2020
The Strength of IL-6/STAT3 Signal Inhibition by SAR S.c q2w Showed Significantly Higher Level Than That of TCZ S.c q2w but Lower Than TCZ S.c q1w
Shuntaro Saito¹, Katsuya Suzuki², Keiko Yoshimoto², Yasushi Kondo², Jun Kikuchi², Kotaro Otomo², Hironari Hanaoka², Yuko Kaneko² and Tsutomu Takeuchi³, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan
Background/Purpose: Interleukin-6 (IL-6) is a key cytokine in the pathogenesis of rheumatoid arthritis (RA). Tocilizumab (TCZ) and Sarilumab (SAR) are monoclonal antibodies that bind to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.